AI Visibility Snapshot · INO
How AI and terminals describe INOVIO PHARMACEUTICALS, INC.
This snapshot is built only from your public SEC EDGAR record, the same machine-readable data that AI assistants and financial terminals read first. Confirmed facts only.
Ticker INO · CIK 0001055726 · generated October 22, 2026
We found 2 items that affect how AI and terminals describe INO.
SEC classification: Pharmaceutical Preparations (SIC 2834)
Worth checkingYour SEC industry code says "Pharmaceutical Preparations," while market data lists you under "Biotechnology." When classifications disagree, AI assistants and terminals pick one, and it is often the wrong one.
SEC records show a former name: GENETRONICS BIOMEDICAL LTD
Needs attentionEDGAR lists INO as formerly "GENETRONICS BIOMEDICAL LTD" (through 2001-08-03). After a name change or reverse merger, AI engines and terminals routinely keep returning the old identity for the ticker. Investors searching INOVIO PHARMACEUTICALS, INC. may be shown the prior company, its old business, and its old numbers.
Recent SEC filing activity (last filing 2026-10-06)
Looks cleanYou are producing current primary disclosures. The open question is whether AI sources and terminals are actually reading them, which the full audit verifies.
Listed on Nasdaq
Looks cleanA national-exchange listing helps, but listed companies are still routinely misdescribed by AI assistants when their structured data is stale.
Get the full 24-hour AI Visibility audit
This page reads your public SEC record. The full Pulse IR audit adds what it cannot see: how ChatGPT, Perplexity, and Google AI actually answer "what is INO", how the major terminals (FactSet, S&P, Refinitiv, Bloomberg, TradingView) list you, whether you have a verified knowledge-graph entity, and the exact corrections to file. Delivered in 24 hours, free, no obligation. Enter your work email and we will send it.
For company management and investor relations. Pulse IR is the investor-relations firm behind PubCo Insight.
Every finding above is a confirmed public fact from SEC EDGAR. This is educational research about public data, not investment advice, and not a statement about the merits of the security.